Get access

Meeting the challenge of recurrent Clostridium difficile infection

Authors

  • Stuart Johnson MD

    Corresponding author
    1. Division of Infectious Diseases, Department of Medicine, Loyola University Medical School, Maywood, Illinois
    • Division of Infectious Diseases, Department of Medicine, Loyola University Medical School, 2160 S First Ave, Bldg 54, Room 149, Maywood, IL 60153
    Search for more papers by this author
    • Telephone: 708-216-3232


  • Disclosure: Consultant: Astellas Pharma, Bio-K+, Cubist Pharmaceuticals, Pfizer, Optimer Pharmaceuticals, and ViroPharma. The author received support for travel and an honorarium from Paradigm Medical Communications for time and expertise spent writing this article.

Abstract

Recurrent Clostridium difficile infection (CDI) is a growing problem that poses significant management challenges. There is no strong evidence to support a particular treatment strategy for recurrent CDI, especially those with multiple recurrences. However, a key strategy for reducing recurrent CDI is prompt diagnosis and treatment, facilitated by early recognition of patients at risk for recurrence. Journal of Hospital Medicine 2012;7:S11–S13. © 2012 Society of Hospital Medicine

Ancillary